Anti his tag sc8036

Antibodies used in this study were as follows: anti-USP15 (A300-923A, WB: 1:1000), anti-BARD1 (A300-263A, WB: 1:1000; IF: 1:200), and anti-RAP80 (A300-764A, WB: 1:1000; IF: 1:100) were purchased from Bethyl Laboratory. Anti-HP1γ (MABE656, WB: 1:2000). Mouse anti-γ-H2AX (05-636, IF: 1:500), mouse anti-MDC1 (05-1572, IF: 1:300) and mouse anti-FK2 (04-263, IF: 1:200) were purchased from Millipore. Anti-RPA 70 (#2267, IF: 1:200), rabbit anti-γ-H2AX (#9718, IF: 1:400), and rabbit anti-HA (#3724, WB: 1:2500; IF: 1:300) were from Cell signaling Technology. Anti-Rad51 (GTX100469, IF: 1:200) were from Genetex. Anti-BRCA1 (D9, IF: 1:50) and anti-His tag (sc8036, WB: 1:1000) were from Santa Cruz. Anti-poly PAR (4336-BPC-100, WB: 1:1000) were from Trevigon. Anti-53BP1 (NB100-304, WB: 1:1000; IF: 1:300) were from Novus Biologicals. Anti-RNF8 (14112-1-AP, IF: 1:100) were from Proteintech. Rabbit anti-FLAG (F7425, WB: 1:2500) and mouse anti-FLAG (F3165, WB: 1:2500) were from Sigma-Aldrich. Mouse anti-HA (901501, WB: 1:2500; IF: 1:100) were from BioLegend.

S/FLAG/SBP‐tagged TPD52 was generated in the pIRES2‐EGFP vector. HA‐tagged TPD52 was generated in the pCMV‐HA vector. TPD52 cDNA was cloned in pGEX‐4 T‐2 to generate GST fusion protein expression plasmids. His‐tagged AMPKα, β, and γ expression constructs were generated from pET‐28a. TPD52 deletion mutants were generated using site‐directed mutagenesis (Stratagene).
The following antibodies were used: phospho‐AMPKα (2535S), AMPKα (5832S), AMPKβ (4150S), AMPKγ (4187S), phospho‐ACC1 (3661S), ACC1 (3662S) from CST, TPD52 (GTX115042) from GeneTex, anti‐His tag (sc8036) from Santa Cruz, anti‐FLAG (F7425, F3165) from Sigma‐Aldrich, and anti‐HA (901501) from Biolegend.
siRNAs against TPD52 (Thermo Fisher Scientific) were as follows: 5’‐GCGGAAACUUGGAAUCAAU‐3′ (siTPD52‐1) and 5’‐GGAGAAGUCUUGAAUUCGG‐3′ (siTPD52‐2). Nontargeting siRNA (All‐star negative control siRNA) was purchased from QIAGEN.